Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA(A) receptor complex.
A large number of structurally different classes of ligands, many of them sharing the main characteristics of the benzodiazepine (BDZ) nucleus, are active in the modulation of anxiety, sedation, convulsion, myorelaxation, hypnotic and amnesic states in mammals. These compounds have high affinity for the benzodiazepine binding site (BDZ-bs) of the GABA(A) receptor complex. Since 1989 onwards our laboratories established that some natural flavonoids were ligands for the BDZ-bs which exhibit medium to high affinity in vitro and anxiolytic activity in vivo. Further research resulted in the production of synthetic flavonoid derivatives with increased biochemical and pharmacological activities. The currently accepted receptor/pharmacophore model of the BDZ-bs (Zhang, W.; Koeler, K. F.; Zhang, P.; Cook, J. M. Drug Des. Dev. 1995, 12, 193) accounts for the general requirements that should be met by this receptor for ligand recognition. In this paper we present a model pharmacophore which defines the characteristics for a ligand to be able to interact and bind to a flavone site, in the GABA(A) receptor. closely related to the BDZ-bs. A model of a flavone binding site has already been described (Dekermendjian, K.; Kahnberg, P.; Witt, M. R.; Sterner, O.; Nielsen, M.; Liljerfors, T. J. Med. Chem. 1999, 42, 4343). However, this alternative model is based only on graphic superposition techniques using as template a non-BDZ agonist. In this investigation all the natural and synthetic flavonoids found to be ligands for the BDZ-bs have been compared with the classical BDZ diazepam. A QSAR regression analysis of the parameters that describe the interaction demonstrates the relevance of the electronic effects for the ligand binding, and shows that they are associated with the negatively charged oxygen atom of the carbonyl group of the flavonoids and with the nature of the substituent in position 3'.
Marder
M
M
Instituto de Química y Fisicoquímica Biológicas, Faultad de Farmacia y Bioquímica, Buenos Aires, Argentina.
Estiú
G
G
Blanch
L B
LB
Viola
H
H
Wasowski
C
C
Medina
J H
JH
Paladini
A C
AC
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism; D001569:Benzodiazepines / Q000378:metabolism*; D001665:Binding Sites; D003975:Diazepam / Q000737:chemistry; D004347:Drug Interactions; D005419:Flavonoids / Q000378:metabolism*; D005445:Flunitrazepam / Q000378:metabolism; D008024:Ligands; D008958:Models, Molecular; D021281:Quantitative Structure-Activity Relationship; D011869:Radioligand Assay; D051381:Rats; D011963:Receptors, GABA-A / Q000378:metabolism*; D013574:Synaptosomes / Q000378:metabolism
D014151:Anti-Anxiety Agents; D005419:Flavonoids; D008024:Ligands; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D005445:Flunitrazepam; D003975:Diazepam